secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001104659-25-076153
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q2 2025 revenue $20.2M (+26% YoY); net loss narrows to $9.9M; reaffirms FY2025 guidance $85M-$88M
--------------------------------------------------------------------------------

- Revenue $20.2M (+26% YoY); OviTex PRS product revenue up 53% YoY.
- Net loss $9.9M vs $12.6M in prior-year quarter; operating loss $9.1M improved from $11.6M.
- Gross margin improved to 69.8% vs 68.8% due to lower excess/obsolete inventory charge.
- Appointed Jeffrey Blizard as President effective June 2025 to strengthen commercial leadership.
- Reaffirmed FY2025 revenue guidance of $85M-$88M (23-27% YoY growth); cash $35.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465925076153/0001104659-25-076153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465925076153/tm2522957d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-076153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer